©The Author(s) 2025.
World J Nephrol. Dec 25, 2025; 14(4): 110749
Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.110749
Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.110749
Table 3 Commonly encountered uropathogens with their susceptible antibiotics
| Bacteria | Antibiotics |
| Escherichia coli | Nitrofurantoin, Trimethoprim-sulfamethoxazole, Fosfomycin |
| Staphylococcus saprophyticus | Nitrofurantoin, Norfloxacin Trimethoprim-sulfamethoxazole |
| Enterococcus faecalis | Ampicillin, Vancomycin (for resistant strains) |
| Pseudomonas aeruginosa | Ceftazidime, Piperacillin-tazobactam, Meropenem, Ciprofloxacin, Aminoglycosides |
| Klebsiella pneumoniae | Ceftriaxone, Piperacillin-tazobactam, Fluoroquinolones (if susceptible), Aminoglycosides |
| Proteus mirabilis | Trimethoprim-sulfamethoxazole, Ciprofloxacin |
| Enterobacter spp. | Cefepime (less resistant strains), Fluoroquinolones (susceptible), Aminoglycosides (serious infections) |
| Coagulase-negative Staphylococci spp. | Vancomycin (for resistant strains), Oxacillin (if susceptible) |
- Citation: Pandey S, Aravaanan ASK, Bhaskar E, Silambanan S. Biomarkers innovation in urinary tract infections: Insights into pathophysiology, antibiotic resistance, and clinical applications. World J Nephrol 2025; 14(4): 110749
- URL: https://www.wjgnet.com/2220-6124/full/v14/i4/110749.htm
- DOI: https://dx.doi.org/10.5527/wjn.v14.i4.110749